Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

BioNTech SE

Moderna

Pfizer

They still might offer solid long-term opportunities for investors.

After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?

Nuvaxovid™ will be the first protein-based vaccine available for adolescents aged 12 through 17 in the United Kingdom GAITHERSBURG, Md. , Aug. 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

The superior reactogenicity profile of Novavax's Nuvaxovid vaccine could make it the preferred choice amongst some in an endemic COVID environment. The company's other promising vaccine, NanoFlu, is being overlooked due to the market's focus on COVID.

Novavax: Finding Its Niche

Novavax was authorized for adults last month. Health officials now say kids as young as 12 can get Novavax.

CDC Recommends Novavax for Teens: What to Know About the Newest COVID Shot

Investors weren't impressed with the company's latest victory on the regulatory front.

Why Novavax Fell Today Despite Its Sunny News

Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.

Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents

The story of Novavax stock over the last few years would make an amazing book.

The Rise and Fall of Novavax

Novavax announced on Saturday that its Covid-19 vaccine has been authorized for emergency use by the FDA for adolescents between the ages of 12 and 17.

FDA authorizes emergency use for Novavax Covid-19 vaccine for ages 12 and 17

The Food and Drug Administration authorized Novavax Inc.'s NVAX, -2.58% COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. MRNA, -2.60% and BioNTech SE BNTX, +0.21% , and received an emergency-use authorization by the FDA for adults in July.

Novavax COVID-19 vaccine authorized for U.S. teens

Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received GAITHERSBURG, Md. , Aug. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks. The post Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions appeared first on Investor's Business Daily.

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

FuboTV

Your money is safer in the bank than with these stocks.

2 Overrated Growth Stocks I Wouldn't Buy With Free Money

Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md. , Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Apple

AMC Entertainment

VanEck Vectors Social Sentiment ETF

DoorDash

FOMO ETF

GameStop

Marathon Digital Holdings

Roundhill Meme ETF

MicroStrategy Incorporated

Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.

Missed BBBY? 10 'Meme Stocks' Are Next Gold Mines, Analysts Say

Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md. , Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a heterologous and homologous booster dose in adults aged 18 and older.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

Investors were cheered by the potential for widened authorizations of the Nuvaxovid vaccine.

Why Novavax Stock Eked Out a Gain Today

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

Novavax Inc. NVAX, +2.80% said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA authorization in July.

Novavax submits FDA application for its COVID-19 booster

If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

bluebird bio

Investing in biotech stocks without any drugs on the market can be scary. These suggestions can help you make money in this high-risk sector.

2 Tips for Investing in Biotech Stocks With High Growth Potential

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 2.80% to $41.47, though off the session high of $43.06 after the company announced its Novaxovid COVID-19 vaccine has been approved in South Korea for use in adolescents aged 12 through 17. What Happened?

Here's Why Novavax Stock Is Trading Higher

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md. , Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.

Why Novavax Stock Was Plummeting This Week

Believe it or not, Novavax's revenue could decline and still cause the stock to soar.

News for Novavax Stock (NVAX)